ECG vs. HALO
ECG (Everus Construction Group Inc) and HALO (Halozyme Therapeutics, Inc.) are both stocks. ECG operates in Engineering & Construction (Industrials), while HALO operates in Biotechnology (Healthcare). Over the past year, ECG returned 152.49% vs 30.97% for HALO. At a 0.12 correlation, their price movements are largely independent.
Performance
ECG vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ECG achieves a 77.65% return, which is significantly higher than HALO's 3.74% return.
ECG
- 1D
- 0.82%
- 1M
- 0.71%
- YTD
- 77.65%
- 6M
- 63.65%
- 1Y
- 152.49%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
HALO
- 1D
- 5.34%
- 1M
- 8.13%
- YTD
- 3.74%
- 6M
- 7.98%
- 1Y
- 30.97%
- 3Y*
- 27.65%
- 5Y*
- 12.08%
- 10Y*
- 21.91%
ECG vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
ECG Everus Construction Group Inc | 77.65% | 30.13% | 34.18% |
HALO Halozyme Therapeutics, Inc. | 3.74% | 40.77% | -5.25% |
Correlation
The correlation between ECG and HALO is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Oct 29, 2024 | 0.12 |
Fundamentals
ECG:
$7.78B
HALO:
$8.58B
ECG:
$4.37
HALO:
$2.87
ECG:
34.80
HALO:
24.37
ECG:
2.03
HALO:
2.75
ECG:
1.96
HALO:
5.64
ECG:
11.33
HALO:
39.06
ECG:
$3.96B
HALO:
$1.51B
ECG:
$492.32M
HALO:
$1.23B
ECG:
$334.68M
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ECG vs. HALO — Risk / Return Rank
ECG
HALO
ECG vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Everus Construction Group Inc (ECG) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ECG | HALO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.69 | ||
| Sortino ratioReturn per unit of downside risk | +1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.19 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 7.57 | 1.29 | +6.28 |
| Martin ratioReturn relative to average drawdown | 20.37 | 2.47 | +17.90 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ECG | HALO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.72 | 1.04 | +1.69 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.31 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.51 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 1.66 | 0.23 | +1.43 |
Drawdowns
ECG vs. HALO - Drawdown Comparison
The maximum ECG drawdown since its inception was -56.23%, smaller than the maximum HALO drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for ECG and HALO.
Loading charts...
Drawdown Indicators
| ECG | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -56.23% | -74.26% | +18.03% |
Max Drawdown (1Y)Largest decline over 1 year | -20.26% | -24.13% | +3.87% |
Max Drawdown (3Y)Largest decline over 3 years | — | -33.92% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -49.06% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -49.06% | — |
Current DrawdownCurrent decline from peak | -10.14% | -14.05% | +3.91% |
Average DrawdownAverage peak-to-trough decline | -14.02% | -31.91% | +17.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.52% | 12.55% | -5.03% |
Volatility
ECG vs. HALO - Volatility Comparison
Everus Construction Group Inc (ECG) has a higher volatility of 16.31% compared to Halozyme Therapeutics, Inc. (HALO) at 11.55%. This indicates that ECG's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ECG | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.31% | 11.55% | +4.76% |
Volatility (6M)Calculated over the trailing 6-month period | 45.46% | 24.29% | +21.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 56.46% | 30.34% | +26.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 62.91% | 39.53% | +23.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 62.91% | 42.91% | +20.00% |
Dividends
ECG vs. HALO - Dividend Comparison
Neither ECG nor HALO has paid dividends to shareholders.
Financials
ECG vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Everus Construction Group Inc and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ECG vs. HALO - Profitability Comparison
ECG - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Everus Construction Group Inc reported a gross profit of 130.73M and revenue of 1.04B. Therefore, the gross margin over that period was 12.6%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
ECG - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Everus Construction Group Inc reported an operating income of 77.68M and revenue of 1.04B, resulting in an operating margin of 7.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
ECG - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Everus Construction Group Inc reported a net income of 58.32M and revenue of 1.04B, resulting in a net margin of 5.6%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
ECG and HALO have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ECG has higher volatility (16.31%) compared to HALO (11.55%). In terms of maximum drawdown, ECG dropped -56.23% vs HALO's -74.26%.
ECG currently has the higher Sharpe Ratio (2.72 vs 1.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ECG and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer